Drugs / Tegoprubart
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06972069 | May 2025 → Dec 2030 expected | disease related to solid organ transplantation, kidney failure | Tatsuo Kawai, MD, PhD | Recruiting | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT07592000 | Apr 2027 → Jan 2030 expected | chronic kidney disease, type 1 diabetes mellitus | University of Chicago | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06305286 | Mar 2024 → Mar 2029 expected | type 1 diabetes mellitus | University of Chicago | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05480657 | Sep 2022 → Aug 2024 | type 1 diabetes mellitus | Eledon Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT05027906 | Feb 2022 → Jan 2027 expected | — | Eledon Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT06126380 | Oct 2023 → Dec 2029 expected | transplant rejection | Eledon Pharmaceuticals | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT05983770 | Aug 2023 → Sep 2025 | transplant rejection | Eledon Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT05125068 | Mar 2022 → Jul 2023 | IgA glomerulonephritis | Eledon Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT04711226 | Feb 2021 → Jun 2024 | type 1 diabetes mellitus | Anelixis Therapeutics, LLC | Withdrawn | No outcome recorded |
| Phase 2 | NCT04322149 | Oct 2020 → Mar 2022 | amyotrophic lateral sclerosis | Anelixis Therapeutics, LLC | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tegoprubart | “This study aimed to assess the safety, tolerability, and impact on pro-inflammatory biomarker profiles of an anti CD40L antibody, tegoprubart, in individuals with amyotrophic...” PMID 39480764 ↗ Oct 2024 |
| Known as | AT-1501 | “Tegoprubart (AT-1501) is a monoclonal antibody for Injection is a humanized immunoglobulin G1 (IgG1) kappa monoclonal anti-CD40L antibody that blocks CD40L binding to its...” NCT06305286 ↗7“AT-1501 monoclonal antibody targeting CD40L given as an IV infusion” NCT04322149 ↗ |
| Action | Inhibit | “a humanized monoclonal antibody antagonist to CD40 ligand (CD40L)” NCT04322149 ↗ |
| Modality | Monoclonal antibody | “a humanized monoclonal antibody antagonist to CD40 ligand (CD40L)” NCT04322149 ↗ |
| Route | Intravenous | “AT-1501 monoclonal antibody targeting CD40L given as an IV infusion” NCT04322149 ↗ |
| Target | CD40LG | “AT-1501 monoclonal antibody targeting CD40L given as an IV infusion” NCT05027906 ↗ |